ABBV-552
- Generic Name
- ABBV-552
A Study to Assess the Mass Balance of [14C] ABBV-552 in Healthy Male Participants Following Single Oral Dose Administration
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 8
- Registration Number
- NCT06278766
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Inc /ID# 262684, Madison, Wisconsin, United States
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
Phase 2
Completed
- Conditions
- Alzheimer's Disease (AD)
- Interventions
- Drug: Placebo for ABBV-552
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 240
- Registration Number
- NCT05771428
- Locations
- 🇺🇸
Irvine Clinical Research /ID# 250030, Irvine, California, United States
🇺🇸Alliance for Research Alliance for Wellness /ID# 246492, Long Beach, California, United States
🇺🇸Wake Research - Pharmacology Research Institute (WR-PRI), LLC (Alamitos) /ID# 248891, Los Alamitos, California, United States
A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Through the Body of Healthy Adult Japanese and Han Chinese Participants
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 18
- Registration Number
- NCT05686980
- Locations
- 🇺🇸
Anaheim Clinical Trials LLC /ID# 252203, Anaheim, California, United States
🇺🇸PPD Clinical Research Unit -Las Vegas /ID# 252241, Las Vegas, Nevada, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath